3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Neurofibromatosis 1
1
Neurofibroma, Plexiform
1
Interventions
Carboplatin
36
Cisplatin
32
pembrolizumab
30
Paclitaxel
29
Pemetrexed
22
Gemcitabine
21
Nivolumab
19
Dexamethasone
17
Rituximab
16
Fluorouracil
13
Docetaxel
13
durvalumab
12
Ipilimumab
12
Capecitabine
12
Cyclophosphamide
11
atezolizumab
10
130-nm albumin-bound paclitaxel
10
olaparib
9
Trastuzumab
9
Lenalidomide
9
Doxorubicin
9
Cytarabine
9
Bevacizumab
9
daratumumab
8
Oxaliplatin
8
Bortezomib
8
Vinorelbine
7
Prednisone
7
Leucovorin
7
venetoclax
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Has announcements
×
AZD 6244
×
Clear all
NCT04924608
2026-03-23
KOMET
AstraZeneca
Phase 3
Active not recruiting
145 enrolled
17 charts
1 FDA